首页> 美国卫生研究院文献>Cancers >Current State of Surgical Management of Pancreatic Cancer
【2h】

Current State of Surgical Management of Pancreatic Cancer

机译:胰腺癌外科治疗的现状

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Pancreatic cancer is still associated with a poor prognosis and remains—as the fourth leading cause of cancer related mortality—a therapeutic challenge. Overall long-term survival is about 1–5%, and in only 10–20% of pancreatic cancer patients is potentially curative surgery possible, increasing five-year survival rates to approximately 20–25%. Pancreatic surgery is a technically challenging procedure and has significantly changed during the past decades with regard to technical aspects as well as perioperative care. Standardized resections can be carried out with low morbidity and mortality below 5% in high volume institutions. Furthermore, there is growing evidence that also more extended resections including multivisceral approaches, vessel reconstructions or surgery for tumor recurrence can be carried out safely with favorable outcomes. The impact of adjuvant treatment, especially chemotherapy, has increased dramatically within recent years, leading to significantly improved postoperative survival, making pancreatic cancer therapy an interdisciplinary approach to achieve best results.
机译:胰腺癌的预后仍然很差,并且作为癌症相关死亡率的第四大诱因,仍然是治疗上的挑战。总体长期生存率约为1–5%,只有10–20%的胰腺癌患者有可能进行根治性手术,从而将五年生存率提高到大约20–25%。胰腺手术是一项技术难题,过去数十年来,在技术方面以及围手术期护理方面已发生了重大变化。在高容量机构中,可以进行标准化切除,以降低发病率和死亡率低于5%。此外,越来越多的证据表明,可以安全地进行包括多脏器入路,血管重建或肿瘤复发手术在内的更多扩大的切除术,并取得良好的效果。近年来,辅助治疗(尤其是化学疗法)的影响已显着增加,导致术后生存期显着改善,因此胰腺癌治疗成为一种跨学科的方法,可达到最佳效果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号